BR112017023951A2 - derivados de etinila - Google Patents

derivados de etinila

Info

Publication number
BR112017023951A2
BR112017023951A2 BR112017023951-5A BR112017023951A BR112017023951A2 BR 112017023951 A2 BR112017023951 A2 BR 112017023951A2 BR 112017023951 A BR112017023951 A BR 112017023951A BR 112017023951 A2 BR112017023951 A2 BR 112017023951A2
Authority
BR
Brazil
Prior art keywords
lower alkyl
halogen
substituted
pyridinyl
pyrimidinyl
Prior art date
Application number
BR112017023951-5A
Other languages
English (en)
Inventor
Jaeschke Georg
O'hara Fionn
Plancher Jean-Marc
Ricci Antonio
Rueher Daniel
Vieira Eric
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of BR112017023951A2 publication Critical patent/BR112017023951A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Abstract

a presente invenção refere-se a compostos da fórmula i i em que r1 é hidrogênio, f ou cl, l é uma ligação ou alquileno inferior, r2 é -(ch2)no- alquila inferior, alquila inferior substituída com halogênio, ?(ch2)nc(o)o- alquila inferior, fenila substituída com alquila inferior ou halogênio, ou é um grupo heteroarila de 5 ou 6 membros selecionados a partir de piridinila, pirimidinila, piridazinila, tiazolila, imidazolila, pirazolila ou triazolila, que são opcionalmente substituídos com alquila inferior, halogênio, alcóxi inferior, =o, benziloxi, cicloalquiloxi, hidróxi, ciano, alquila inferior substituída com halogênio ou com ?(ch2)no - alquila inferior, n é 1, 2 ou 3, r3 é hidrogênio, alquila inferior ou -(ch2)no-alquila inferior, r4 é fenila, piridinila ou pirimidinila, opcionalmente substituída com f, y é cf ou ccl, ou a um sal ou sal de adição ácida aceitável farmaceuticamente, a uma mistura racêmica, ou a seu enantiômero correspondente e/ou isômero ótico e/ou estereoisômeros dos mesmos. os compostos podem ser usados tratamento de doença de parkinson, ansiedade, êmeses, transtorno obsessivo compulsivo, autismo, neuroproteção, câncer, depressão e diabetes tipo 2.
BR112017023951-5A 2015-08-03 2016-08-02 derivados de etinila BR112017023951A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15179550.7 2015-08-03
EP15179550 2015-08-03
PCT/EP2016/068359 WO2017021384A1 (en) 2015-08-03 2016-08-02 Ethynyl derivatives

Publications (1)

Publication Number Publication Date
BR112017023951A2 true BR112017023951A2 (pt) 2018-07-24

Family

ID=53776452

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023951-5A BR112017023951A2 (pt) 2015-08-03 2016-08-02 derivados de etinila

Country Status (21)

Country Link
US (1) US10011607B2 (pt)
EP (1) EP3331882B1 (pt)
JP (1) JP6975511B2 (pt)
KR (1) KR20180030857A (pt)
CN (1) CN107667107B (pt)
AR (1) AR105556A1 (pt)
AU (1) AU2016302696B2 (pt)
BR (1) BR112017023951A2 (pt)
CA (1) CA2983908A1 (pt)
CL (1) CL2018000278A1 (pt)
CO (1) CO2017011010A2 (pt)
HK (1) HK1246790A1 (pt)
IL (1) IL255103B (pt)
MX (1) MX2018001486A (pt)
PE (1) PE20180357A1 (pt)
PH (1) PH12018500247A1 (pt)
RU (1) RU2722014C9 (pt)
TW (1) TWI621619B (pt)
UA (1) UA120888C2 (pt)
WO (1) WO2017021384A1 (pt)
ZA (1) ZA201707015B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180686A1 (es) 2015-08-03 2018-04-23 Glenmark Pharmaceuticals Sa Compuestos nuevos como moduladores de ror gamma
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
BR112018001960A2 (pt) 2015-08-03 2018-09-18 Bristol-Myers Squibb Company compostos heterocíclicos úteis como moduladores de tnf alfa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005248A (es) * 2009-11-06 2012-06-14 Univ Vanderbilt Aril- y heteroaril-sulfonas como potenciadores alostericos de mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica.
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
EP2702050B1 (en) * 2011-04-26 2016-05-18 F.Hoffmann-La Roche Ag Pyrazolidin-3-one derivatives
DK3049409T3 (en) * 2013-09-25 2017-07-10 Hoffmann La Roche ethynyl derivatives
TWI649310B (zh) * 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
AU2015222303B2 (en) * 2014-02-25 2019-02-28 F. Hoffmann-La Roche Ag Ethynyl derivatives

Also Published As

Publication number Publication date
EP3331882B1 (en) 2020-04-29
IL255103B (en) 2020-01-30
CO2017011010A2 (es) 2018-02-09
TWI621619B (zh) 2018-04-21
CA2983908A1 (en) 2017-02-09
MX2018001486A (es) 2018-03-15
WO2017021384A1 (en) 2017-02-09
RU2018105872A (ru) 2019-09-05
ZA201707015B (en) 2018-11-28
UA120888C2 (uk) 2020-02-25
IL255103A0 (en) 2017-12-31
HK1246790A1 (zh) 2018-09-14
US10011607B2 (en) 2018-07-03
AU2016302696B2 (en) 2020-05-07
AU2016302696A1 (en) 2017-11-02
AR105556A1 (es) 2017-10-18
CL2018000278A1 (es) 2018-07-06
RU2722014C2 (ru) 2020-05-26
CN107667107A (zh) 2018-02-06
PE20180357A1 (es) 2018-02-21
CN107667107B (zh) 2021-05-18
RU2722014C9 (ru) 2020-10-22
JP2018522037A (ja) 2018-08-09
KR20180030857A (ko) 2018-03-26
PH12018500247A1 (en) 2018-08-13
JP6975511B2 (ja) 2021-12-01
RU2018105872A3 (pt) 2019-12-26
EP3331882A1 (en) 2018-06-13
TW201718589A (zh) 2017-06-01
US20180127429A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
PE20220253A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112016010168A2 (pt) derivados de etinil-imidazolina-2,4-diona como moduladores de mglur4
BR112012015168A2 (pt) "derivados de benzamida substituída".
BR112015005186A2 (pt) 2-oxo-2,3-di-hidro-indóis para tratamento de distúrbios do snc
BR112017023951A2 (pt) derivados de etinila
PH12016500427A1 (en) Ethynyl derivatives
BR112014015832A2 (pt) derivados heterocíclicos como receptores associados com aminas vistigiais (taars)
BR112013021848A2 (pt) 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina-carboxamidas como moduladores de mglur5
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
PE20230834A1 (es) Antagonistas del receptor de lpa y usos de los mismos
EA200970911A1 (ru) Хинолины и их терапевтическое применение
BR112015016323A2 (pt) agonistas de receptor de oxitocina para tratamento de doenças de cns
BR112016017816A8 (pt) derivados de etinila, seus usos, e composição farmacêutica
AR104863A1 (es) Derivados imidazol
AR103952A1 (es) Derivados de pirimidina-diona
BR112019000314A2 (pt) derivados de etinila
AR105327A1 (es) Derivados de imidazol
BR112015002921A2 (pt) derivados de ariletinila.
BR112015009990A2 (pt) derivados de pirazina
AR102599A1 (es) 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
BR112012032576A2 (pt) derivados de amino-tropano

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements